Clinical Trials Logo

Cutaneous T-Cell Lymphoma clinical trials

View clinical trials related to Cutaneous T-Cell Lymphoma.

Filter by:

NCT ID: NCT00969085 Withdrawn - Clinical trials for Cutaneous T-cell Lymphoma

Trial of Curcumin in Cutaneous T-cell Lymphoma Patients

Start date: November 2012
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if treatment with curcumin can help to decrease the size of lesions and/or decrease itching in patients with MF or SS. The safety of curcumin will also be studied.

NCT ID: NCT00896493 Completed - Clinical trials for Lymphoma, Non-Hodgkin

Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma

Start date: May 2009
Phase: Phase 2
Study type: Interventional

Non-myeloablative approach for allogeneic transplant is a reasonable option, especially given that the median age at diagnosis is 55-60 years and frequently present compromised skin in these patients, which increases the risk of infection. Therefore, we propose a clinical study with allogeneic hematopoietic stem cell transplantation (HSCT) using a unique non-myeloablative preparative regimen, TLI/ATG, to treat advanced mycosis fungoides/Sezary syndrome (MF/SS).

NCT ID: NCT00863395 Terminated - Clinical trials for Cutaneous T-Cell Lymphoma

Recalcitrant Pruritus in Cutaneous T-Cell Lymphoma

CTCL
Start date: December 2008
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to define the mechanisms that underlie the refractory pruritus (itch) in Cutaneous T-Cell Lymphoma (CTCL).

NCT ID: NCT00779896 Recruiting - Clinical trials for Cutaneous T-Cell Lymphoma

Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study

Start date: October 2008
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open label, prospective study to evaluate therapeutic potential of Tazarotene 0.1% cream for the treatment of Stage I-IIA CTCL. Patients with Stage I-IIA disease are enrolled into the study. Tazarotene will be used for up to 24 weeks and patients will be followed for up to 12 months.

NCT ID: NCT00744991 Completed - Clinical trials for Cutaneous T-Cell Lymphoma

A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma

Start date: September 2008
Phase: Phase 2
Study type: Interventional

The purpose of the study is to determine the efficacy and safety of enzastaurin in participants with Cutaneous T-Cell Lymphoma (CTCL) who failed prior therapies.

NCT ID: NCT00699296 Terminated - Clinical trials for Cutaneous T-Cell Lymphoma

Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma

Start date: May 2008
Phase: Phase 2
Study type: Interventional

This study will assess the safety, efficacy and pharmacokinetics of oral LBH589 in Japanese adult patients with refractory cutaneous T-Cell Lymphoma and adult T-cell leukemia/lymphoma. LBH589 is administered orally once a day for three days per week.

NCT ID: NCT00554827 Completed - Clinical trials for Cutaneous T-cell Lymphoma

Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Start date: August 2007
Phase: Phase 1
Study type: Interventional

This study is being conducted to identify how much and how often pralatrexate, given with vitamin B12 and folic acid, can be given safely to patients with cutaneous T-cell lymphoma (CTCL) that has relapsed (returned after responding to previous treatment) or is refractory (has not responded to previous treatment). It is also being conducted to get information on whether or not pralatrexate is effective in treating relapsed or refractory CTCL.

NCT ID: NCT00490776 Terminated - Clinical trials for Cutaneous T-Cell Lymphoma

Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL)

Start date: July 5, 2007
Phase: Phase 2
Study type: Interventional

This study evaluated the safety and efficacy of LBH589B in adult participants with refractory/resistant Cutaneous T-Cell Lymphoma and prior Histone Deacetylase (HDAC) inhibitor therapy.

NCT ID: NCT00431912 Completed - Clinical trials for Cutaneous T-cell Lymphoma

A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma

Start date: February 2007
Phase: Phase 2
Study type: Interventional

This phase II study is designed to determine the efficacy and safety of APO866 for the treatment of patients with advanced forms of cutaneous T-cell lymphoma (CTCL). APO866 has shown to induce growth inhibition in cultures of human CTCL cells as well as in animal models with subcutaneously implanted human CTCL tumors. APO866 was considered to be safe and well-tolerated in a phase I study that treated 24 patients with advanced cancer. APO866 is administered by intravenous infusion continuously for 96 hours and that is repeated every 4 weeks. Patients will receive 3 cycles of treatment and the primary efficacy endpoint will be assessed at Week 16. patients will be followed up for 12 months

NCT ID: NCT00425555 Completed - Clinical trials for Cutaneous T-Cell Lymphoma

Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma

Start date: January 2007
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of LBH489B in adult patients with refractory Cutaneous T-Cell Lymphoma.